A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF EVOLOCUMAB (AMG 145) ON LDL-C IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA/MIXED DYSLIPIDEMIA

Registry ID

20130287

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

AMGEN CANADA INC

Start date

2016-06-02

Completion date

2017-11-29

Last update

2016-04-29

Conditions

• TYPE 2 DIABETES
• HYPERCHOLESTEROLEMIA
• MIXED DYSLIPIDEMIA

Related clinical trials

• A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ELECOGLIPRON COMPARED WITH ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS (ELUMINATE-2)
• A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-WEEKLY RO7795068 ADMINISTERED TO PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES
• EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-BIASED, ULTRA LONG-ACTING GLP-1RA, IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED, PLACEBO-CONTROLLED TRIAL (VESPER-5)
• EFFICACY AND SAFETY OF CAGRILINTIDE FOR WEIGHT MANAGEMENT IN PARTICIPANTS WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (RENEW 2)
• A PHASE I/II, RANDOMISED, SINGLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-ASCENDING-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF AZD9550 MONOTHERAPY AND CO-ADMINISTRATION OF AZD9550 AND AZD6234 IN PARTICIPANTS LIVING WITH OBESITY AND OVERWEIGHT WITH OR WITHOUT TYPE 2 DIABETES MELLITUS
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ONCE-WEEKLY CT-388 ADMINISTERED SUBCUTANEOUSLY FOR 48 WEEKS TO PARTICIPANTS WHO ARE OVERWEIGHT OR OBESE WITH TYPE 2 DIABETES MELLITUS

View on source registry